APVO — Aptevo Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $0.45m
- -$16.45m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 12.4 | 40 | 45 | 22.6 | 16.9 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 7.02 | 2.37 | 3.66 | 2.5 | 0 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 30 | 47.3 | 52.6 | 27.4 | 19.1 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 7.69 | 5.54 | 3.96 | 6.76 | 5.78 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 53.4 | 53.5 | 56.6 | 34.2 | 24.8 |
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 38.2 | 14.5 | 34.8 | 8.71 | 7.22 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 41.6 | 37 | 55.4 | 16.2 | 12.6 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 11.8 | 16.6 | 1.22 | 18 | 12.2 |
Total Liabilities & Shareholders' Equity | 53.4 | 53.5 | 56.6 | 34.2 | 24.8 |
Total Common Shares Outstanding |